PRIMEX-PHARMACEUTICALS
Swiss pharmaceutical company Primex Pharmaceuticals AG and French pharmaceutical laboratory Advicenne SA announced today a deal where Primex will acquire global rights for an advanced oral pharmaceutical candidate for pediatric anesthesiology developed by Advicenne. The market potential is evaluated as hundreds of millions of euros.
This oral solution is dedicated to pediatric anesthesiology. Nearly 10,000 patients have already been successfully treated by the university hospital at Amiens, which collaborated with Advicenne.
With this acquisition, Primex Pharmaceuticals expands its anesthesiology portfolio with a unique product that will be distributed through Primex’s existing channels and new partners, which will be appointed in all other markets.
“This is a breakthrough in the area of pediatric anesthesia, and along with further applications, the annual market potential is between 100 M€ and 350 M€”, says Kari Sarvanto, President of Primex Pharmaceuticals. “We’re extremely enthusiastic about the cooperation with Advicenne and looking forward to bringing such a patient-friendly novel product to the market.”
“As one of the very first in-house developed products, this deal validates our strategy and capabilities in developing original pediatric-adapted drugs”, says Dr Luc-André Granier, CEO of Advicenne. “Primex Pharmaceuticals is probably the best partner for the commercial success of the product as its network is global and its commitment for anesthesiology is very strong.”
About Advicenne, www.advicenne.com
Advicenne, a fast-growing specialty pharma, focuses on innovative pediatric medications, targeting orphan or neglected diseases within the fields of neurology and nephrology and aims to become a world leader in those therapeutic areas.
The company has today a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and epilepsy, and has started its commercial activities late 2015 with its first product on the French market.
About Primex Pharmaceuticals
Primex Pharmaceuticals is a fast-growing company spearheading a new pharmaceutical business model. It supplies high-quality anesthetics and life-saving medicines to healthcare institutions and professionals around the world. Primex’s distribution reaches a population of nearly one billion people. The company is headquartered in Finland and Switzerland.
Primex Pharmaceuticals has proven underlying business operations and historical strong revenue growth (29 % CAGR in 2012-2015E) and high margins (adjusted EBITDA margin 12% on average 2012-2015E).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160222005746/en/
Contact:
Primex Pharmaceuticals
Mr Kari Sarvanto, President
Mobile:
+41 796 162 694
Email: kari.sarvanto@primexintl.com
or
For
Advicenne
ComCorp
Ms Adélaïde Manester
Mobile:
+33 1 58 18 32 44
+33 6 70 45 74 37
Email: amanester@comcorp.fr
or
Ms
Anne Hardy
Mobile: +33 1 58 18 32 51
+33 6 13 56 23 96
Email:
ahardy@comcorp.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lineage Expands Nordic Presence with Strategic Acquisition of Permanor AS in Norway6.5.2025 09:00:00 CEST | Press release
Lineage completes acquisition of Permanor AS, strengthening its cold storage and logistics capabilities across Norway and the broader Nordic region. The operations and property in Haugesund and the operations in Brumunddal will enhance Lineage’s ability to serve the Nordic region’s meat and food industry, with a focus on sustainability and energy efficiency. Lineage, Inc. (NASDAQ: LINE) (“Lineage”), the world’s largest global temperature-controlled warehouse REIT, today announced that it has completed the acquisition of Permanor AS, a leading provider of cold storage and logistics solutions in Norway. The acquisition includes Permanor AS’s operations and property in Haugesund and Brumunddal, further strengthening Lineage’s footprint in the Nordics market and enhancing its ability to serve the region’s growing food supply chain. Permanor AS specializes in freezing, thawing, storage, and logistics services, primarily catering to the meat manufacturing industry, alongside handling baked g
Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 20256.5.2025 08:00:00 CEST | Press release
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies Agendia®, Inc., today announced that new data from its ongoing FLEX Study will be presented at the upcoming ESMO BreastCancer 2025 congress taking place May 14-17 in both Munich, Germany and virtually. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505212759/en/ The FLEX Study (NCT03053193) is a prospective real-world evidence, observational breast cancer study designed to correlate whole transcriptome gene expression in early-stage breast cancer with clinical outcomes, and to evaluate how genomic insights can inform treatment decisions in early-stage breast cancer. In this analysis, researchers examined the impact of BluePrint, Agendia’s 80-gene molecular subtyping assay, on pathological complete response (pCR) rates and chemothera
Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x6.5.2025 06:15:00 CEST | Press release
K Navigator increases researcher productivity by 20x¹, accelerating biomedical breakthroughs and outperforming leading generalist LLMs Analyzes and visualizes multimodal patient data, plus exclusive access to MOSAIC Window, a subset of the world’s largest spatial omics dataset in oncology Built by biologists, for biologists. Free to use for academic researchers.² Owkin, a leading agentic AI company, has launched K Navigator, an AI-powered research co-pilot designed to revolutionize biomedical science. K Navigator is an agentic playground where researchers can explore, refine, and validate hypotheses, accelerating the quality and pace of their discoveries. With K Navigator, Owkin moves closer to its vision of developing the world’s first Biological Artificial Superintelligence (BASI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505282917/en/ K Navigator home screen. A single natural language interface - K Navigator enab
NIKE, Inc. Announces Senior Leadership Changes to Accelerate Growth and Drive Win Now Action Plan5.5.2025 22:15:00 CEST | Press release
Amy Montagne Becomes President, NikePhil McCartney Becomes EVP, Chief Innovation, Design & Product OfficerNicole Graham Becomes EVP, Chief Marketing OfficerTom Clarke Becomes Chief Growth Initiatives OfficerHeidi O’Neill to Retire NIKE, Inc. (NYSE:NKE) announced a series of strategic changes to its Senior Leadership Team (SLT), elevating experienced leaders to accelerate progress against its Win Now action plan to position the company for future growth. Elliott Hill, President and CEO, NIKE, Inc. and Heidi O’Neill, President of Consumer, Product, and Brand, have decided the Consumer, Product, and Brand leadership will now be divided into three distinct areas: Consumer and Sport, Marketing, and Product Creation, inclusive of Innovation and Design. These roles will now report directly to Hill. As a result of these changes O’Neill has decided to retire from Nike after 26 years. She will continue to serve in an advisory capacity until September 2025. “For nearly three decades, Heidi has be
LR Health & Beauty Once Again Demonstrates Its Expertise in Aloe Vera5.5.2025 16:24:00 CEST | Press release
The social commerce company develops a unique combination of Aloe Vera Gel and fermented Aloe LR Health & Beauty has been synonymous with the best Aloe Vera quality on the market for over 20 years, and continuously invests in new product innovations to take full advantage of the plant's range of beneficial properties. The majority of the over 60 products are developed and produced directly at the company headquarters in Ahlen. LR has now made a decisive breakthrough in skin care cosmetics with its unique combination of pure Aloe Vera leaf gel and fermented Aloe Vera. The care products with the highest Aloe Vera content therefore not only work in the upper and middle layers of the skin, but also unleash the full potential of Aloe Vera in the deeper layers. The effectiveness of this LR Aloe Via Magic Power Duo has been confirmed by the dermatological institute, Dermatest. All the products tested based on a combination of Aloe Vera Gel and fermented Aloe were awarded the 5-star "very good
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom